Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris

Kragballe, Knud; Noerrelund, Kirsten Lykke; Lui, Harvey; Ortonne, Jean‐Paul; Wozel, Gottfried; Uurasmaa, Tutta; Fleming, Colin; Estebaranz, J. L. López; Hanssen, Leif I.; Persson, Lill-Marie

doi:10.1111/j.1365-2133.2004.05986.x

Cited by 86 publications

(122 citation statements)

References 16 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…In our study population, the results obtained after the initial phase with Dovobet" could be maintained or further improved with treatment with Daivonex" alone, as shown by previous studies (7,9).…”

Section: Discussionsupporting

confidence: 65%

See 1 more Smart Citation

Treatment of Psoriasis Vulgaris with Calcipotriol Betamethasone Dipropionate Combination Followed by Calcipotriol and Assessment of the Adjuvant Basic Use of Urea-Based Emollients

Cassano

Agnusdei

et al. 2005

Eur J Inflamm

View full text Add to dashboard Cite

A new combination product containing betamethasone dipropionate and calcipotriol (Dovebet" ointment) has been proven very effective and well tolerated in patients with psoriasis vulgaris. Emollients are adjunctive modalities commonly used in psoriasis; however, their actual role in combination with topical drugs as well as well as their compatibility with these drugs have not been well elucidated. In 313 adult patients with psoriasis vulgaris, we studied the efficacy and tolerability of treatment with Dovobet" ointment combined with urea-based emollients (Excipial U®) for 4 weeks, followed by treatment with calcipotriol (Daivonex") either alone (group A) or combined with urea-containing emollients (Excipial U®, group B) for 8 weeks. Clinical evaluations were performed at baseline, at 4 and 12 weeks, assessing the clinical score for erythema, scaling, infIltration and pruritus, graded on the basis of a 5-point scale. After the initial 4-week treatment, a significant improvement of all clinical parameters was observed (p

show abstract

Section: Discussionsupporting

confidence: 65%

“…Clinical studies have shown that the combination product has greater efficacy and tolerability and a faster speed of onset than either agent used alone (5)(6)(7)(8)(9)(10). It is usually administered once daily for up 4 weeks followed by maintenance treatments with steroid-free conventional products (e.g., calcipotriol alone).…”

mentioning

confidence: 99%

Treatment of Psoriasis Vulgaris with Calcipotriol Betamethasone Dipropionate Combination Followed by Calcipotriol and Assessment of the Adjuvant Basic Use of Urea-Based Emollients

Cassano

Agnusdei

et al. 2005

Eur J Inflamm

View full text Add to dashboard Cite

show abstract

“…Although calcitriol and calcipotriol (a synthetic VDR ligand) have been approved as topical agents for the treatment of mild to moderate psoriasis, their use (especially oral) has at least in some cases been associated with an increased incidence of hypercalcemia/ hypercalciuria (10)(11)(12)(13)(14), and they exhibit poor efficacy when compared with biologics (15). In the clinic, the therapeutic efficacy of calcitriol and calcipotriol is increased by their use in combination with topical steroids (16,17). Therefore, there is an unmet clinical need for the identification of a new generation of VDR ligands that exhibit an improved therapeutic index (TI).…”

Section: Introductionmentioning

confidence: 99%

Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators

Khalifa²,

Yee³

et al. 2006

Journal of Clinical Investigation

108

View full text Add to dashboard Cite

Vitamin D receptor (VDR) ligands are therapeutic agents for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism. VDR ligands also show immense potential as therapeutic agents for autoimmune diseases and cancers of skin, prostate, colon, and breast as well as leukemia. However, the major side effect of VDR ligands that limits their expanded use and clinical development is hypercalcemia that develops as a result of the action of these compounds mainly on intestine. In order to discover VDR ligands with less hypercalcemia liability, we sought to identify tissue-selective VDR modulators (VDRMs) that act as agonists in some cell types and lack activity in others. Here, we describe LY2108491 and LY2109866 as nonsecosteroidal VDRMs that function as potent agonists in keratinocytes, osteoblasts, and peripheral blood mononuclear cells but show poor activity in intestinal cells. Finally, these nonsecosteroidal VDRMs were less calcemic in vivo, and LY2108491 exhibited more than 270-fold improved therapeutic index over the naturally occurring VDR ligand 1,25-dihydroxyvitamin D 3 [1,25-(OH) 2 D 3 ] in an in vivo preclinical surrogate model of psoriasis.

show abstract

“…[10][11][12][13][14][15] The two-compound ointment appears to have an improved tolerability profile vs. either compound alone; this may be due to the vitamin D analogue and steroid components each neutralizing the side-effects of the other agent (e.g. atrophy and tachyphylaxis ⁄ rebound effect may be reduced by the presence of the vitamin D analogue, and irritation may be reduced by the presence of the steroid).…”

Section: Combination Therapy Provides Enhanced Efficacymentioning

confidence: 99%

What is new in topical therapy for psoriasis?

Reich

Bewley

2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

This article describes a recent development in topical therapies for psoriasis and is based on a presentation given by the authors at a satellite symposium convened during the 19th Congress of the European Academy of Dermatology and Venereology, 6-10 October 2010, in Gothenburg, Sweden. Topical therapies are the mainstay of treatment for psoriasis; however, for optimal outcomes to be achieved, medications need to be used as prescribed. Patients with psoriasis often report low treatment adherence rates; the reasons for this are multifactorial, but can include specific aspects of the treatments themselves. For example, physical properties, ease of use and the vehicle in which the active ingredients are dissolved can all play a role in an individual patient's adherence to treatment. Of the available topical therapies, corticosteroids and vitamin D analogues are the treatment of choice, with combined efficacy that is superior to monotherapy with either agent. To permit simultaneous once-daily dosing, an ointment was formulated that allowed calcipotriol and betamethasone dipropionate to be delivered together; this twocompound ointment had an improved efficacy and tolerability profile vs. either compound alone. To provide an alternative for patients who may dislike ointments, but still want to benefit from the high efficacy of combination therapy, a two-compound (calcipotriol ⁄ betamethasone dipropionate) gel has recently been developed; data from phase 2 and phase 3 studies show that it is more effective than the comparators it was tested against, with fewer adverse events, and a rapid onset of action. In a series of one-to-one interviews recently conducted with 150 patients with psoriasis, gel and cream formulations were preferred for ease of use and cosmetic acceptability compared with ointment. The availability of this new gel thus increases patient choice. Ultimately, treatment should always be tailored to match individual patients' needs.

show abstract

Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris

Abstract: Two different short-term treatment regimens employing a recently developed two-compound product (calcipotriol/betamethasone dipropionate) provided rapid and marked clinical efficacy and were shown to be safe therapies for psoriasis vulgaris.

Cited by 86 publications

References 16 publications

Treatment of Psoriasis Vulgaris with Calcipotriol Betamethasone Dipropionate Combination Followed by Calcipotriol and Assessment of the Adjuvant Basic Use of Urea-Based Emollients

Treatment of Psoriasis Vulgaris with Calcipotriol Betamethasone Dipropionate Combination Followed by Calcipotriol and Assessment of the Adjuvant Basic Use of Urea-Based Emollients

Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators

What is new in topical therapy for psoriasis?

Contact Info

Product

Resources

About